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Abstract
 
By transgenic expression of ovalbumin (OVA) as a model self antigen in the 
 
 
 
 cells of the
pancreas, we have shown that self tolerance can be maintained by the cross-presentation of this
antigen on dendritic cells in the draining lymph nodes. Such cross-presentation causes initial
activation of OVA-specific CD8 T cells, which proliferate but are ultimately deleted; a process
referred to as cross-tolerance. Here, we investigated the molecular basis of cross-tolerance. De-
letion of CD8 T cells was prevented by overexpression of Bcl-2, indicating that cross-tolerance
was mediated by a Bcl-2 inhibitable pathway. Recently, Bim, a pro-apoptotic Bcl-2 family
member whose function can be inhibited by Bcl-2, was found to play a critical role in the de-
letion of autoreactive thymocytes, leading us to examine its role in cross-tolerance. Bim-defi-
cient T cells were not deleted in response to cross-presented self-antigen, strongly implicating
Bim as the pro-apoptotic mediator of cross-tolerance.
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Introduction
 
CD8 T cells recognize antigen presented by MHC class I
molecules. Access of antigen to the MHC class I presenta-
tion pathway was originally thought to be restricted to en-
dogenous proteins, i.e., those expressed within the cyto-
plasm of the cell presenting the antigen. It has subsequently
been shown, however, that under certain circumstances
professional APCs, such as dendritic cells (DCs),
 
*
 
 can
present exogenous antigens in the class I pathway (1, 2); a
process referred to as cross-presentation (3). In an immuno-
genic response, the advantage of cross-presentation is that
proteins from pathogens that do not infect DCs can still be
processed in the MHC class I pathway of such professional
APCs, allowing them to prime naive CD8 T cells, a pro-
cess termed cross-priming (4).
Tissue-associated self-antigens can also be cross-pre-
sented by DCs (2). This creates the potential for autoimmu-
nity when antigens whose expression is limited to periph-
eral tissues are cross-presented to autoreactive CD8 T cells.
However, we have shown that cross-presentation of self
antigen leads to deletion of naive, autoreactive CD8 T
cells. This process, termed cross-tolerance, is preceded by
the activation and limited proliferation of autoreactive
CD8 T cells (5, 6). Our study seeks to further understand
the molecular mechanisms underlying the deletion of CD8
T cells by cross-tolerance.
Apoptosis is involved in many aspects of the control of
peripheral T cell numbers including: normal cell turnover
in naive (unimmunized) animals, reduction of the pool of
activated, antigen-specific T cells at the termination of an
immune response, and maintenance of peripheral tolerance
to tissue antigens (7, 8). Apoptosis of activated T cells can
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occur either passively or actively. Active apoptosis, or acti-
vation-induced cell death (AICD), is mediated by certain
members of the TNF receptor (TNF-R) superfamily, in-
cluding CD95 (Fas/APO-1) and TNF-R1 (9, 10). Passive
apoptosis, or death by neglect, arises from a lack of survival
signals such as those provided by cytokines or costimula-
tory molecules. A number of studies have shown that
death by neglect can be inhibited by the pro-survival mol-
ecule Bcl-2, both in vitro and in vivo (11). Bcl-2 is a cyto-
plasmic membrane protein that belongs to a family con-
taining both pro- and anti-apoptotic members that act in
concert to control cell survival (12). Mice lacking 
 
bcl-2
 
have decreased numbers of lymphocytes (13–15) and con-
versely, 
 
bcl-2
 
 transgenic mice have enhanced survival of
antigen stimulated lymphocytes and prolonged immune
responses (16–19).
Among the family of Bcl-2–related proteins are anti-
apoptotic members, such as Bcl-2 itself and Bcl-x
 
L
 
, as well
as pro-apoptotic members, which include Bad, Bax, Bim,
and many others (7). Of the pro-apoptotic members, Bim
has recently been reported to play a critical role in T cell
development, being essential for the negative selection of
autoreactive thymocytes (20). Here, we provide evidence
that Bim is required for peripheral deletion mediated by
cross-tolerance, and Bcl-2 overexpression can inhibit this
process.
 
Materials and Methods
 
Mice.
 
All mice were bred and maintained at the Walter and
Eliza Hall Institute for Medical Research. Transgenic, OT-I
(founder C57BL/6 
 
 
 
 C57BL/6-H-2
 
bm1
 
; reference 21), rat insu-
lin promoter (RIP)-membrane-bound OVA (mOVA; founder
C57BL/6-H-2
 
bm1
 
; reference 22), and RIP-OVA
 
hi
 
 (founder
C57BL/6-H-2
 
bm1
 
; reference 23) mice have been described previ-
ously. These mice were all crossed to C57BL/6 mice to achieve
an H-2
 
b
 
 MHC haplotype. RIP-mOVA mice were also crossed to
C57BL/6-H-2
 
bm1
 
 mice to achieve an H-2
 
bm1
 
 MHC haplotype.
Background gene expression for all these transgenic mice was
pure C57BL/6. It should be noted that RIP-mOVA mice de-
velop diabetes when large numbers (
 
 
 
5 
 
 
 
 10
 
6
 
) of naive OT-I
cells are transferred, whereas RIP-OVA
 
hi
 
 mice only develop dia-
betes when activated, but not naive, OT-I cells are adoptively
transferred (23).
Two distinct 
 
bcl-2
 
 transgenic lines were used: 
 
E
 
 
 
-bcl-2–25
(E
 
 
 
-bcl-2)
 
 mice (founder C57BL/6JWehi 
 
 
 
 SJL/JWehi and
backcrossed for 18 generations to C57BL/6), which express
Bcl-2 under the control of the 5
 
 
 
 IgH enhancer (E
 
 
 
) in T cells
(16), and 
 
vav-bcl-2–69 (vav-bcl-2)
 
 transgenic mice (founder
mouse C57BL/6), which express 
 
bcl-2
 
 in all hematopoietic cells
under the control of the 
 
vav
 
 promoter (24). OT-I.E
 
 
 
-Bcl-2
mice were generated by crossing OT-I with the 
 
E
 
 
 
-bcl-2–25
 
line and OT-I.vav-Bcl-2 were generated by crossing OT-I
with 
 
vav-bcl-2–69
 
 mice, provided by Drs. Jerry Adams, Suzanne
Cory, and Alan Harris (The Walter and Eliza Hall Institute of
Medical Research, Melbourne, Victoria, Australia). OT-I.Bim
mice were generated by crossing OT-I mice for two genera-
tions with 
 
bim
 
-deficient mice (line 266; founder C57BL/6 
 
 
 
129/Sv, backcrossed for 10 generations to C57BL/6; refer-
ence 25).
B6.lpr (backcrossed 11 generations to C57BL/6J from MRL/
MpJ donor strain) were obtained from The Jackson Laboratory
and crossed to OT-I mice to generate OT-I.lpr mice
 
Adoptive Transfer and FACS
 
®
 
 Analysis.
 
Preparation of OT-I
cells, carboxy fluorescein diacetate succinimidyl ester (CFSE)-
labeling and analysis on a FACScan™ (Becton Dickinson) were
performed as described previously (5). For adoptive transfer ex-
periments, 5 
 
 
 
 10
 
6
 
 OT-I T cells were intravenously injected into
recipient mice and after 6–8 wk, spleen and lymph nodes were
removed and assessed for the number of OT-I T cells present by
staining with anti-TCR antibodies or tetramers. For antibody
staining anti-V
 
 
 
5-FITC (MR9–4), anti-CD8-PE (Caltag Labs),
and anti-V
 
 
 
2-biotin (B20.1) revealed with Streptavidin Tricolor
(Caltag Labs) were used. For tetramers, OT-I T cells were re-
vealed by staining with K
 
b
 
-OVA
 
257–264
 
 tetramer-PE and anti-
CD8-FITC (Caltag Labs). The total number of OT-I T cells was
determined from the formula: (% OT-I in the CD8
 
 
 
 cells of
adoptively transferred mice 
 
 
 
 background) 
 
 
 
 (% CD8
 
 
 
 T cells
in total live cells) 
 
 
 
 total cell number/10,000. Background was
the % TCRV
 
 
 
5
 
 
 
V
 
 
 
2
 
 
 
 or tetramer
 
 
 
 cells in uninjected mice, on
average this was 1.4% for mAb and 0.1% for tetramer stained
cells. Total cell numbers were determined either by hemocytom-
eter cell count with trypan blue for viability or by flow cytome-
try. For flow cytometry cell number determination, a known
number of small nonfluorescent Sphero™ beads (BD Bio-
sciences) were added to a known volume of the cell sample,
therefore cells/ml 
 
 
 
 number cells collected 
 
 
 
 (numbers beads in
sample/number beads collected)/sample volume.
 
Bone Marrow Chimeras.
 
RIP-mOVA mice expressing the
MHC class I molecule H-2K
 
b
 
 on bone marrow–derived cells and
H-2K
 
bm1
 
 on nonbone marrow–derived tissue (B6 
 
→ 
 
RIP-
mOVA.bm1) were generated as follows. Adult RIP-mOVA.bm1
mice were lethally irradiated, with either one dose of 900 cGy or
two doses of 550 cGy 3 h apart, and reconstituted with 5 
 
 
 
 10
 
6
 
T cell–depleted C57BL/6 bone marrow cells. T cell depletion
was performed by incubating with anti-CD4 (RL172), anti-CD8
(3.168), and anti-Thy1 (J1j) mAbs and treatment with rabbit
complement. On day 1 after reconstitution, all mice were in-
jected intraperitoneally with 100 
 
 
 
g anti-Thy1 mAb (T24) to
eliminate radioresistant host T cells. The mice were left for 8–10
wk before use.
 
Proliferation Assays.
 
RIP-OVA
 
hi
 
 mice or nontransgenic litter-
mate mice were adoptively transferred with OT-I.Bim cells and 4
wk later, lymph node cells were collected. Cells were analyzed by
flow cytometry after staining with anti-CD8 and K
 
b
 
-OVA
 
257–264
 
tetramer to determine the proportion of OT-I.Bim cells pre-
sent. Lymph node cells from these mice or mice that received no
OT-I.Bim cells were titrated in twofold dilutions in 100 
 
 
 
l with
5 
 
 
 
 10
 
5
 
 OVA
 
257–264
 
-coated irradiated (15 Gray) B6 spleen cells in
96 well round-bottom plates. Cultures were pulse with [
 
3
 
H]thy-
midine for 8 h on day 3. To determine OT-I.Bim–specific prolif-
eration, [
 
3
 
H]thymidine incorporation of cultures from mice that
received no OT-I.Bim cells was subtracted from that of the same
lymph node cell concentration for mice containing OT-I.Bim
cells.
 
Results
 
Previously, we have shown that tissue antigens can be
cross-presented on MHC class I molecules of bone mar-
row–derived DCs and that this leads to an initial phase of
proliferation followed by deletion of naive autoreactive 
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CD8 T cells (2, 5). This has been referred to as cross-toler-
ance (6). Our model involves the adoptive transfer of
OVA-specific CD8 T cells from the OT-I transgenic line
(OT-I cells [21]) into RIP-mOVA mice, which express
mOVA under the control of the RIP in the pancreatic is-
lets and the proximal tubule cells of the kidneys (22). Be-
cause we must transfer large numbers of OT-I cells to mea-
sure deletion by flow cytometry, these studies must utilize
B6 
 
→ 
 
RIP-mOVA.bm1 bone marrow chimeras. This pre-
vents damage to islet cells and the induction of diabetes that
would otherwise occur (26). In such chimeras, the MHC
class I molecule K
 
b
 
 is expressed on the bone marrow stem
cell–derived cells and K
 
bm1
 
 on all other tissues. K
 
bm1
 
 is un-
able to present the MHC class I–restricted OVA
 
257–264
 
 pep-
tide SIINFEKL to the OT-I TCR, and this precludes OT-I
cells from attacking RIP-mOVA islet 
 
 
 
 cells. In this report,
we have initially used this model to examine the role of
Bcl-2 in cross-tolerance.
 
Bcl-2 Overexpressing CD8 T Cells Proliferate in Response to
Stimulation by Cross-Presented Self-Antigen.
 
To analyze the
effect of Bcl-2 on deletion by cross-tolerance, OT-I.E
 
 
 
-
Bcl-2 mice were generated by crossing OT-I mice to trans-
genic mice overexpressing Bcl-2 in T cells under the con-
trol of the IgH enhancer (16). Before examining the effect
of overexpression of Bcl-2 on T cell deletion, it was im-
portant to show that OT-I.E
 
 
 
-Bcl-2 cells could respond to
cross-presented self-antigen. To test this, OT-I or OT-
I.E
 
 
 
-Bcl-2 cells were labeled with CFSE and adoptively
transferred into RIP-mOVA mice. After 3 d, cells were re-
covered from the renal (draining) and inguinal (nondrain-
ing) lymph nodes and assessed for proliferation on the basis
of dilution of CFSE fluorescence (Fig. 1). Like OT-I cells,
OT-I.E
 
 
 
-Bcl-2 cells proliferated in the draining lymph
nodes of OVA-expressing mice. The proportion of prolif-
erating OT-I.E
 
 
 
-Bcl-2 cells was slightly decreased com-
pared with control OT-I cells, which is consistent with
previous observations that Bcl-2 overexpression can slow
cell cycle entry (27–29). Nevertheless, OT-I.E
 
 
 
-Bcl-2
cells were clearly capable of detecting and responding to
self-antigen.
 
Bcl-2 Overexpression Prevents Deletion of T Cells by Cross-
Tolerance.
 
To examine the role of Bcl-2 in the deletion of
naive, self-reactive CD8 T cells, OT-I or OT-I.E
 
 
 
-Bcl-2
cells were adoptively transferred into B6 
 
→ 
 
RIP-
mOVA.bm1 chimeras or into control B6 
 
→ 
 
bm1 littermate
chimeras. After 6–8 wk, the number of surviving T cells
was quantitated by counting total cellularity in pooled
spleen and lymph nodes and by immunofluorescent stain-
ing for OT-I TCR expressing T cells. Fig. 2 shows that al-
though most control OT-I cells were deleted in RIP-
mOVA mice (an average of 42 
 
 
 
 10
 
3
 
 cells in RIP-mOVA
mice versus 194 
 
 
 
 10
 
3
 
 cells in nontransgenic mice), OT-
I.E
 
 
 
-Bcl-2 cells increased in number (an average of 1,540 
 
 
 
10
 
3
 
 cells in RIP-mOVA mice versus 472 
 
 
 
 10
 
3
 
 in non-
transgenic mice). This 3–4-fold increase in OT-I.E
 
 
 
-Bcl-2
cells in RIP-mOVA mice compared with nontransgenic
controls would be expected if the deletion process was in-
hibited, as proliferation in the pancreatic and renal nodes
would generate more OT-I.E
 
 
 
-Bcl-2 cells with time.
These results demonstrate that transgenic overexpression of
Bcl-2 prevented the deletion of self-reactive CD8 T cells
by the cross-tolerance mechanism.
 
Bcl-2 Overexpression Does Not Enhance the Seeding of Adop-
tively Transferred CD8 T Cells, but Enhances Their Survival.
 
In addition to preventing deletion by cross-tolerance, Bcl-2
overexpression increased the number of OT-I cells surviv-
ing long term in hosts lacking the OVA antigen (nontrans-
genic mice; Fig. 2). Thus, while 
 
 
 
2   105 OT-I cells
could be found in nontransgenic mice after 6 wk, 5   105
OT-I.E -Bcl-2 cells were evident. Two explanations for
this observation were possible: (a) Bcl-2 expression might
increase the survival of T cells from OT-I mice or (b) it
might allow more efficient initial seeding after adoptive
transfer. To distinguish between these possibilities, RIP-
Figure 1. In vivo proliferation of OT-I and OT-I.E -Bcl-2 CD8 T
cells in response to stimulation by cross-presented self-antigen. 2   106
CFSE-labeled OT-I or OT-I.E -Bcl-2 cells were adoptively transferred
into RIP-mOVA mice. After 52 h, lymphocytes from the draining renal
(left panel) and nondraining inguinal LNs (right panel) were analyzed by
flow cytometry. Profiles were gated on CFSE CD8 PI  cells. The num-
bers indicate the percentage of OT-I cells that have undergone division.
These results are representative of two independent experiments.
Figure 2. The deletion of OT-I cells in response to cross-presentation
of self-antigen is prevented by overexpression of Bcl-2. Bone marrow
from C57BL/6 mice was grafted into irradiated RIP-mOVA.bm1 mice
and nontransgenic (nontg) littermates and the mice were left for 8–12 wk
for reconstitution. 5   106 OT-I or OT-I.E -Bcl-2 cells were then
adoptively transferred, and after a further 6 wk the number of remaining
OT-I cells in the LNs and spleen was determined. Open circles represent
individual mice and the bar and number corresponds to the average num-
ber of OT-I cells per group. These results are representative of five inde-
pendent experiments.950 Bim Is Required for Cross-Tolerance
mOVA and nontransgenic mice were adoptively trans-
ferred with T cells from either OT-I or OT-I.E -Bcl-2
mice, and 3 d later their spleen and lymph nodes were har-
vested and transgenic T cell numbers quantitated (Fig. 3).
This showed that similar numbers of OT-I and OT-I.E -
Bcl-2 cells were found in each group, indicating that the
initial seeding of T cells was not affected by Bcl-2 overex-
pression. This indicated that Bcl-2 promotes long-term
survival of T cells in recipients lacking OVA antigen, a
finding that is consistent with the increased T cell numbers
in unmanipulated bcl-2 transgenic mice (24, 30).
Bcl-2 Overexpression Does Not Enhance Autoimmunity.
As Bcl-2 overexpression inhibited the deletion process and
increased the number of surviving OT-I cells, we specu-
lated that it might also enhance autoimmunity, particularly
as the incidence of diabetes depends on the number of OT-I
cells in this system (5). Table I shows that similar to wild-
type OT-I cells (31), OT-I.E -Bcl-2 cells caused diabetes
in 100% of mice when 5   106 cells were transferred but
no diabetes was evident when 50-fold fewer cells (105 cells)
were transferred. This lower dose is just below the thresh-
old maximum dose for which wild-type OT-I cells have
never caused diabetes (2.5   105). Failure of OT-I.E -
Bcl-2 cells to cause diabetes at this dose indicates that Bcl-2
overexpression alone does not increase the autoimmune
potential of OT-I cells.
The Role of CD95 in Cross-Tolerance. Previously, we
reported that lack of CD95/Fas expression protected OT-I
cells from deletion by the cross-tolerance mechanism (32).
It is surprising that we now find that Bcl-2 overexpression
is protective since in lymphocytes, Bcl-2 and CD95 regu-
late distinct apoptosis signaling pathways (17). Therefore,
we reexamined our original finding with T cells from OT-
I.lpr mice. Subsequent to the 2 original experiments on
which the previous paper was based (32), a further 11 simi-
lar experiments were undertaken. Of the total of 13 exper-
iments performed, 4 showed protection, 2 gave inconclu-
sive results, and 7 showed deletion of OT-I.lpr cells. The
alternative outcomes of protection or deletion were not
random but could be loosely correlated with time as pro-
tection was seen with earlier experiments and only deletion
seen subsequently. A basis for these variable findings
emerged when the genealogy of the donor OT-I.lpr mice
was examined. The mice used in the original study were
derived from an OT-I to B6.lpr mating, with OT-I.lpr
mice then maintained by intercrossing. Subsequently, the
mice were backcrossed to B6.lpr for up to four generations.
Protection from deletion was only observed for T cells
from mice that had been backcrossed to C57BL/6 for 1–3
generations, whereas deletion was observed for mice back-
crossed to C57BL/6 for 3–4 generations. Because of the
observed changes in outcome, we then decided to reestab-
lish the OT-I.lpr line by again mating OT-I mice to B6.lpr
mice and then intercrossing. For this new OT-I.lpr line, 4/5
experiments showed deletion of OT-I.lpr cells (Fig. 4), and
1 experiment was inconclusive. Based on the extensive
studies we have performed since our original finding, we
Figure 3. The initial take of OT-I and OT-I.E -Bcl-2 cells was
equivalent. Bone marrow from C57BL/6 mice was grafted into irradiated
RIP-mOVA.bm1 mice and nontransgenic (nontg) littermates. 4 wk later,
5   106 OT-I or OT-I.E -Bcl-2 cells were adoptively transferred, and
after a further 3 d the number of OT-I cells in the LNs and spleen was
determined. The open circle symbols represent individual mice and the
bar corresponds to the average number of OT-I cells per group. These
results are representative of two independent experiments.
Table I. Diabetes Incidence After Transfer of T Cells to
RIP-mOVA Mice
Number of
injected cells OT-I OT-I.E -Bcl-2 OT-I.Bim
50   105 3/3 5/5 3/3
1   105 0/5 0/9 0/4
Data from three independent experiments. RIP-mOVA mice were
injected with semi-purified OT-I, OT-I.E -Bcl-2, or OT-I.Bim cells
and diabetes assessed by urine glucose analysis. Diabetes onset occurred
between days 5 and 10 and nondiabetic mice were monitored for 100 d.
Wild-type OT-I cells have been examined for diabetes induction in
large numbers of mice in other published experiments (reference 31).
Figure 4. The deletion of OT-I cells in response to cross-presentation
of self-antigen was not prevented by the absence of CD95. Bone marrow
from B6 mice was grafted into irradiated RIP-mOVA.bm1 mice and
nontransgenic (nontg) littermates and mice left 8–12 wk for reconstitu-
tion. 2   106 OT-I or OT-I.lpr cells were adoptively transferred, and af-
ter a further 6–8 wk the number of remaining OT-I cells in the LNs and
spleen was determined. Open circles represent individual mice and the
bar and number corresponds to the average number of OT-I cells per
group. These results are pooled from two independent experiments.951 Davey et al.
must now conclude that CD95 is not essential for deletion
by cross-tolerance.
Further Support for the Ability of Bcl-2 Overexpression to Pre-
vent Deletion by the Cross-Tolerance Mechanism. Because of
the variable results obtained with CD95-deficient OT-I
cells, we considered it critical to independently confirm the
effect of Bcl-2 overexpression using a second bcl-2 express-
ing transgenic line. This time, a Bcl-2 overexpressing OT-I
line was generated by crossing OT-I mice with vav-bcl-2
transgenic mice, which overexpress Bcl-2 under the con-
trol of the vav promoter in all hematopoietic cells, includ-
ing T cells (24). In these studies, we used RIP-OVAhi mice
as our recipients. These mice express secreted OVA protein
in the pancreatic islets (23), and like RIP-mOVA mice, this
causes deletion of OT-I cells via the cross-tolerance mech-
anism. They are more convenient to use than the RIP-
mOVA line, however, as large numbers of naive OT-I cells
fail to cause diabetes and are effectively deleted without the
need to generate chimeric mice. T cells from OT-I, OT-
I.E -Bcl-2 or OT-I.vav-Bcl-2 mice were transferred to
RIP-OVAhi or nontransgenic controls and after 7 wk the
number of surviving transgenic T cells was quantitated
(Fig. 5). This revealed that like the original bcl-2 transgenic
line, OT-I-vav-Bcl-2 cells were protected from cross-tol-
erance deletion in OVA-expressing mice.
Bim-deficient T Cells Are Not Deleted by the Cross-Tolerance
Mechanism. Bim is a pro-apoptotic member of the Bcl-2
protein family and plays a central role in the initiation of
apoptosis signaling (33). Previous studies have shown that
Bim plays a major role in T cell homeostasis (25) and the
deletion of autoreactive thymocytes (20), raising the possi-
bility that it might also play a role in the deletion of mature
T cells by the cross-tolerance mechanism. To examine this
idea, bim-deficient mice were crossed for two generations
to the OT-I line to generate bim-deficient OT-I mice
(OT-I.Bim mice). To ensure that Bim-deficient T cells
could respond to cross-presented self-antigen, OT-I.Bim
cells were labeled with CFSE and adoptively transferred
into RIP-OVAhi mice. As with wild-type OT-I cells, OT-
I.Bim cells proliferated vigorously in response to OVA
cross-presented in the draining pancreatic LN (Fig. 6).
To determine whether Bim expression by T cells was es-
sential for deletion by cross-tolerance, RIP-OVAhi mice
and nontransgenic control mice were adoptively transferred
with OT-I.Bim cells and 4–5 wk later examined for dele-
tion (Fig. 7). As observed with OT-I.E -Bcl-2 and OT-
I.vav.Bcl-2 cells, OT-I.Bim cells were not deleted, but in-
creased in number during their 4–5 wk in vivo. In contrast,
during this time, wild-type OT-I cells were deleted from
RIP-OVAhi mice. These results indicated that the pro-apop-
totic BH3 only protein Bim is essential for deletion by
cross-tolerance.
To investigate the functional status of OT-I.Bim cells
that survived and expanded after transfer into RIP-OVAhi
mice, cells from these mice were examined for their prolif-
erative response to OVA in vitro. These cells were not an-
ergic as they proliferated similarly to OT-I.Bim cells from
nontransgenic recipients (Fig. 8).
Figure 5. The deletion of OT-I cells is prevented by
overexpression of Bcl-2. 5   106 OT-I, OT-I.E -Bcl-2,
or OT-I.vav-Bcl-2 cells were adoptively transferred
into RIP-OVAhi mice and after 7 wk the number of
OT-I cells in the LNs and spleen was determined.
Open circles represent individual mice and the bar and
number corresponds to the average number of OT-I
cells per group. These results are pooled data from
three independent experiments.
Figure 6. In vivo proliferation
of OT-I and OT-I.Bim CD8 T
cells in response to stimulation
by cross-presented self-antigen.
2   106 CFSE-labeled OT-I or
OT-I.Bim cells were adoptively
transferred into RIP-mOVA
mice. After 65 h, lymphocytes
from the draining pancreatic LN
were analyzed by flow cytome-
try. Profiles were gated on
CFSE CD8 PI  cells. The
numbers indicate the percentage
of OT-I cells that have under-
gone division. These results are
representative of two indepen-
dent experiments.952 Bim Is Required for Cross-Tolerance
In a single experiment to assess the autoimmune poten-
tial of OT-I.Bim cells, RIP-mOVA mice were adoptively
transferred with either a high or low dose of OT-I.Bim
cells (Table I). When 5 million cells were transferred OT-
I.Bim cells, like wild-type OT-I cells, caused autoimmu-
nity. When a low dose of 0.1 million OT-I.Bim cells were
transferred, none of four recipient RIP-mOVA mice be-
came diabetic. These data suggested that Bim-deficient cells
were no more autoaggressive than Bim wild-type cells.
Discussion
In this work, we have shown that overexpression of Bcl-2
protects peripheral CD8 T cells from deletion in response
to cross-presented self antigen. The OT-I.E -Bcl-2 and
OT-I.vav.Bcl-2 cells appeared similar to wild-type OT-I
cells in their ability to be activated and proliferate in re-
sponse to cross-presented self-antigen. If sufficiently high
numbers of OT-I.E -Bcl-2 T cells were transferred, they
induced autoimmune diabetes (Table I). As a pro-survival
molecule Bcl-2 protects lymphocytes in vitro and in vivo
against apoptosis induced by growth factor deprivation,
DNA damage or treatment with corticosteroids or calcium
ionophores (16). For activated T cells in vivo, bcl-2 trans-
gene expression prolongs T cell survival following injection
of mice with the superantigen staphylococcus enterotoxin
B (SEB; reference 16), the transfer of HY-TCR CD8 T
cells into male recipients (18), the immunization of mice
expressing a transgenic LCMV-TCR in CD8 T cells with
LCMV peptide (19) and the immunization of mice ex-
pressing a transgenic HEL-TCR in CD4 T cells with HEL
peptide (30). The most likely scenario is that Bcl-2 protects
T cells against “death by neglect” caused by cytokine dep-
rivation or lack of costimulatory ligands as the immune re-
sponse is waning. This is supported by the relationship be-
tween Bcl-2 and signaling through the common   chain
( c) cytokine receptor. Bcl-2 expression is up-regulated in
human (34) or mouse (35) T cells in response to cytokines
using the  c receptor, such as IL-4 and IL-7 and Bcl-2
overexpression promotes T cell development and restores
T cell function in IL-7R–deficient mice (36, 37) and en-
hances T cell development in  c-deficient mice (38).
Therefore, it is logical to speculate that Bcl-2 may protect
cells from cross-tolerance deletion by blocking apoptosis
caused by a cytokine deficiency or absence of costimulator
molecules. Consistent with this notion, CD4 T cells are an
important source of cytokines and potentially able to alter
the costimulatory molecules expressed by DCs. Previously
we have shown that Ag-specific CD4 T cells can impair
the deletion of CD8 T cells in response to self-Ag (26).
Death receptors and members of the Bcl-2 protein family
regulate distinct apoptosis signaling pathways (12, 17). Al-
though Bcl-2 can protect against apoptosis induced by ne-
glect, CD95 is a critical mediator for the AICD of cycling T
cells that have previously been activated through their
TCR (9, 10). In lymphocytes, Bcl-2 and CD95 have been
shown to regulate independent pathways of apoptosis (17),
although under some physiological conditions both path-
ways can be activated and are additive in their effects. In
E -bcl-2 transgenic lpr/lpr (CD95-deficient) mice, the dele-
tion in response to superantigen SEB immunization was
completely abrogated (17) and lymphadenopathy was more
severe than that caused by either mutation alone (17, 39).
Although we initially described a role for CD95 in me-
diating cross-tolerance (32), this effect was lost when the
donor OT-I.lpr mice were further backcrossed suggesting
the original protective effect may have been the result of
genetic drift, changes in microflora, or incomplete purity of
C57BL/6 background genes. It is notable that all experi-
ments performed here used mice on a C57BL/6 back-
ground (OT-I, B6.lpr, and RIP-mOVA or RIP-OVAhi
mice), so background genes should have been identical, but
it cannot be excluded that the B6.lpr line still carried other
MRL background genes despite the 11 backcrosses to
C57BL/6 reported by its source, The Jackson Laboratory.
Interestingly, MRL mice have been reported to have a de-
Figure 7. The deletion of OT-I cells is prevented by bim deficiency.
5   106 OT-I or OT-I.Bim cells were adoptively transferred into RIP-
OVAhi mice and after 4–5 wk the number of OT-I cells in the LNs and
spleen was determined. The open circle symbols represent individual
mice and the bar and number corresponds to the average number of OT-I
cells per group. These results are pooled data from two independent ex-
periments and are representative of data from five experiments.
Figure 8. OT-I.Bim CD8 T cells that fail to be deleted in RIP-OVAhi
mice are not anergic. Proliferation in response to OVA257–264 peptide-
coated spleen cells by OT-I.bim cells recovered from RIP-OVAhi mice
(filled symbols) or nontransgenic mice (open symbols) 4 wk after adoptive
transfer. These results are representative of three separate experiments.953 Davey et al.
fect in B cell receptor ligation-induced AICD (40), raising
the possibility that a gene(s) causing this phenotype may
also impair T cell deletion. Alternatively, as we have previ-
ously shown that provision of CD4 T cell help abrogates
deletion of OT-I T cells in response to cross-presentation
of self-antigen (26), it is possible that minor antigens of
MRL origin in the early generations of the OT-I.lpr line
were able to stimulate CD4 T cell help thereby preventing
deletion of the OT-I.lpr cells. From the data presented
here we now conclude that the pathway for cross-tolerance
involves Bcl-2 but is independent of CD95.
Contrary to the results here, it has been found that loss
of CD95 but not Bcl-2 overexpression could protect CD4
T cells from apoptosis induced by stimulation with self-
antigen (30). This disparity may reflect a differential role for
CD95 in CD4 versus CD8 T cells. In vitro CD8 T cells
show greater sensitivity to TNF  than FasL induced apop-
tosis (41), whereas in vivo models of virus infection have
shown that CD8 T cell responses are unchanged in the ab-
sence of CD95 and TNF-R (42–45). Alternatively, the in-
volvement of CD95 versus Bcl-2 regulated apoptosis sig-
naling pathways may result from differences in TCR/
MHC affinity or the quantity, nature, or manner of presen-
tation of the self antigen. For example, it has been shown
that Bcl-2 expression can be altered by the affinity of
TCR/MHC interactions (46, 47). With respect to the na-
ture of the self-ligand, it is worth pointing out that when
CD4 T cells were protected from deletion by CD95
deficiency, the self-antigen was ubiquitously expressed,
whereas in our case the antigen is expressed locally and is
cross-presented. Hence, whether death receptors or the
Bcl-2–regulated apoptosis signaling pathway is activated
may be determined by the site of antigen expression or the
type of cells presenting the antigen.
In this study, Bcl-2 overexpression protected CD8 T
cells from deletion in response to cross-presented self-anti-
gens. This indicates that Bcl-2 itself or a functional homo-
logue (e.g. Bcl-x, Bcl-w, A1, or Mcl-1) is downregulated,
or the function of a pro-apoptotic family member is up-
regulated, to cause T cell death during cross-tolerance in-
duction. Interestingly, thymocytes lacking the pro-apop-
totic Bcl-2 family member Bim, were shown to be
resistant to negative selection in the thymus (20), leading
us to examine a role for Bim in deletion by cross-toler-
ance. As shown by the use of Bim-deficient T cells in
adoptive transfer experiments, the absence of Bim pre-
vented their deletion, leading to a dramatic accumulation
of autoreactive T cells. The amount of T cell accumula-
tion caused by Bim deficiency was similar to that caused
by Bcl-2 overexpression indicating that Bim is the critical
initiator of apoptosis during the cross-tolerance deletion
process. A role for Bim in peripheral T cells has also been
recently reported in the deletion of activated T cells after
their response to SEB in vivo (48). Bim is normally re-
tained in an inactive form in the microtubular dynein mo-
tor complex by binding to dynein light chain DLC1/LC8
(49). How it is released from this complex during cross-
tolerance induction is as yet unknown.
Interestingly, despite a failure to delete Bim-deficient
OT-I cells, there was no apparent enhancement of autoim-
munity (Table I) even though the surviving OT-I.Bim
cells were not anergic (Fig. 8). The simplest explanation for
these findings is that activation by cross-presented self-anti-
gen is insufficient to generate full effector function in au-
toreactive T cells. Sherman and colleagues provide support
for this view, showing that CD8 T cells activated by cross-
presented self antigens are functionally different from those
primed by virus (50). This suggests that, in this situation,
the major potential problem with failing to delete autoreac-
tive Bim-deficient CD8 T cells might relate to their con-
tinued availability for activation into fully functional au-
toreactive effectors if further stimulated by antigens in the
context of infection.
In conclusion, we have demonstrated that Bim is essen-
tial for the deletion of autoreactive CD8 T cells induced by
cross-presentation of self-antigens, thereby providing a link
between the mechanisms responsible for central and pe-
ripheral tolerance and illustrating the importance of the
Bcl-2 family of proteins in self-tolerance.
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